Km. Radomski et al., COLLABORATION BETWEEN PHARMACY AND LABORATORY - DEFINING TOTAL ALLOWABLE ERROR LIMITS FOR THERAPEUTICALLY MONITORED DRUGS, The Annals of pharmacotherapy, 32(2), 1998, pp. 170-175
OBJECTIVE: To define the total allowable variability that is clinicall
y tolerated for certain drug assays performed by the therapeutic drug
assays performed by the therapeutic drug monitoring (TDM) laboratory a
t our institution. METHODS: The monthly coefficient of variation (CV)
for 13 of the most commonly performed drug assays was recorded for two
concentrations the upper and lower limits of the therapeutic range fo
r each drug. A dosing simulation was performed for each drug by using
population parameters to estimate the doses that would yield the two t
arget concentrations in an adult patient. The smallest practical dosag
e adjustment that could be implemented in clinical practice was determ
ined and the serum concentration resulting from this dosage change was
estimated. Each change was equated to two standard deviations from th
e original drug concentration, and the corresponding CV or total allow
able error (TEa) was calculated and compared with the laboratory's CV
value. RESULTS: The laboratory CV was greater than the clinically defi
ned TEa for amikacin at both trough and peak ranges, and for gentamici
n and tobramycin at the trough range. Simulations for a patient with c
ompromised renal function produced TEa values less than the reported C
V for amikacin at both trough and peak ranges. Simulations for an obes
e patient produced TEa values less than the reported CV for amikacin,
gentamicin, and tobramycin at both trough and peak ranges. The assay v
ariability for these aminoglycosides is greater than the expected chan
ge in serum drug concentrations produced by the dosage changes used in
the simulations. The TEa for all other drugs exceeded the laboratory
CV, demonstrating assay variability within the clinically tolerated ra
nge. CONCLUSION: Knowledge of how the variability of a drug assay comp
ares with its TEa allows clinicians to assess the usefulness of a seru
m drug concentration as a clinical tool.